10-Q: LENSAR Q2 2025: Revenue Growth Amidst Alcon Merger Review

LENSAR, Inc. reports increased revenue and reduced net loss for Q2 2025, driven by ALLY System placements, while its acquisition by Alcon faces extended FTC review.

Summary

• Total revenue for the three months ended June 30, 2025, increased by 10% to $13.9 million, compared to $12.6 million in the same period of 2024.
• Total revenue for the six months ended June 30, 2025, increased by 21% to $28.1 million, compared to $23.2 million in the same period of 2024.
• Net loss for the three months ended June 30, 2025, significantly decreased to $1.8 million, compared to $9.0 million in the same period of 2024.
• Net loss for the six months ended June 30, 2025, increased to $29.1 million, compared to $11.2 million in the same period of 2024, primarily due to a $17.4 million change in fair value of warrant liabilities.
• Product revenue for the three months ended June 30, 2025, grew 14% to $10.9 million, and for the six months, it grew 29% to $21.8 million, driven by ALLY System placements and procedure volume.
• Selling, general and administrative expenses increased by 72% in the three months ended June 30, 2025, to $11.7 million, and by 68% for the six months to $22.8 million, largely due to $4.2 million (Q2) and $8.4 million (6 months) in acquisition-related costs for the Alcon merger.
• The proposed merger with Alcon Research, LLC, for $14.00 cash per share plus a $2.75 contingent value right (CVR) upon achieving 614,000 cumulative procedures by December 31, 2027, is undergoing an extended FTC review.
• The company received a $10.0 million cash deposit related to the Alcon merger.
• Total procedure volume for the six months ended June 30, 2025, was 104,447, compared to 169,506 for the full year 2024.
• The installed base of Systems (LENSAR Laser System and ALLY Robotic Cataract Laser System) is approximately 410 as of June 30, 2025.

Sentiment

Score: 6

Explanation: While revenue growth is positive and Q2 net loss improved, the significant YTD net loss, ongoing operating losses, substantial acquisition-related costs, and regulatory delays for the merger and product clearances introduce considerable uncertainty and risk. The potential for future capital raises and competitive pressures also temper enthusiasm.

Positives

• Total revenue increased by 10% in Q2 2025 and 21% for the six months ended June 30, 2025, driven by ALLY System placements and procedure volume.
• Net loss for Q2 2025 significantly decreased to $1.8 million from $9.0 million in Q2 2024.
• Recurring revenue represented 82% of total revenue in Q2 2025 and 81% for the six months ended June 30, 2025, indicating a stable revenue base.
• The ALLY System has received regulatory clearances or certifications in the U.S., European Union, India, Taiwan, and South Korea, expanding its market reach.
• The company holds $7.15 million in cash and cash equivalents and $13.16 million in short-term investments as of June 30, 2025, and expects sufficient liquidity for at least 12 months.
• A $10.0 million cash deposit was received in connection with the pending Alcon merger.

Negatives

• Net loss for the six months ended June 30, 2025, increased to $29.1 million from $11.2 million in the prior year, primarily due to a $17.4 million non-cash change in the fair value of warrant liabilities.
• Selling, general and administrative expenses increased significantly by 72% in Q2 2025 and 68% for the six months, largely due to $8.4 million in acquisition-related costs for the Alcon merger.
• Lease revenue decreased by 16% in Q2 2025 and 9% for the six months, primarily due to a decrease in leased LLS units.
• Gross profit margin has been negatively impacted by tariffs on imported raw materials for ALLY Systems and PIDs, as these additional costs have not been passed on to customers.
• The company has incurred recurring operating losses since inception and expects to continue incurring losses and cash outflows for the near-term future.
• Revenue in South Korea has been reduced due to changes in insurance benefits for cataract surgeries, negatively impacting demand in the region.

Risks

• The proposed merger with Alcon may not be consummated or may be delayed due to regulatory approvals, including an extended FTC review.
• The announcement or failure to consummate the merger could negatively impact business, financial condition, results of operations, or stock price.
• Restrictions on business activities under the Merger Agreement could limit the company's ability to respond to competitive pressures or take advantage of business opportunities.
• Securities class action and derivative lawsuits in connection with the merger could result in substantial costs and prevent or delay its consummation.
• Economic uncertainty, including increased inflation, rising interest rates, and tariffs, could adversely affect revenue, profit margins, cash flow, and liquidity.
• The company expects to incur operating losses for the near-term future and cannot assure achievement or sustainment of profitability.
• Commercial success of the ALLY System depends on obtaining additional regulatory clearances/certifications and achieving significant market acceptance.
• Patients may not be willing to pay the price difference for advanced cataract procedures using LENSAR's systems, as these are typically not covered by Medicare or private insurance.
• Inability to effectively grow the U.S. sales and marketing organization or maintain/grow an effective network of international distributors could adversely affect business prospects.
• Future capital needs are uncertain, and additional funds may not be available on acceptable terms or at all, potentially leading to dilution for existing stockholders.
• Material disruption to the supply or manufacture of Systems or component parts, including supply chain shortages and price increases, could negatively affect operating results.
• The company faces intense competition from other medical device companies, some with longer operating histories, more established products, or greater resources.
• International business operations are subject to risks such as staffing difficulties, increased competition, longer payment cycles, reduced intellectual property protection, tariffs, currency fluctuations, and political instability.
• Products and operations are subject to extensive government regulation and oversight, and failure to comply could harm the business.
• Delays or failure to receive necessary clearances, certifications, or approvals for future products or modifications to current products would adversely affect business growth.
• The company's success depends on its ability to obtain, maintain, and protect its intellectual property rights, which could be challenged, invalidated, or infringed.
• Misuse or off-label use of products may harm reputation, result in product liability suits, or lead to costly investigations, fines, or sanctions by regulatory bodies.
• Products may cause or contribute to adverse medical events or be subject to failures/malfunctions requiring reporting, with failure to report leading to sanctions.
• The clinical trial process is lengthy, expensive, and has uncertain outcomes, and results of earlier studies may not be predictive of future clinical trial results.
• Legislative or regulatory reforms in the United States or the EU may make it more difficult and costly to obtain regulatory clearances, certifications, or approvals.
• The company is subject to federal, state, and foreign laws pertaining to healthcare fraud and abuse, including anti-kickback, self-referral, false claims, and fraud laws, with potential for fines or other penalties for violations.
• The company is subject to anti-corruption, anti-bribery, and similar laws (e.g., FCPA), and any violations could result in fines or other penalties.
• Reliance on information technology and the use of AI Technologies involve significant technological and legal risks, including cybersecurity threats, data breaches, and evolving regulatory frameworks.
• The large number of shares eligible for public sale could depress the market price of common stock.
• North Run Capital and its affiliates' significant ownership (45.6% voting power) may limit other stockholders' ability to influence corporate matters.
• The company does not anticipate paying cash dividends, requiring stockholders to rely on stock appreciation for any return on investment.
• Certain provisions in charter documents and Delaware law could discourage takeover attempts and lead to management entrenchment.
• The designated exclusive forums for certain litigation may limit stockholders' ability to obtain a favorable judicial forum for disputes.
• The trading price of common stock is likely to be highly volatile due to various factors, including market performance, product introductions, and regulatory changes.
• The company is obligated to develop and maintain proper and effective internal control over financial reporting, which is burdensome and costly.
• Increasing scrutiny and stakeholder expectations regarding environmental, social, and governance (ESG) matters may cause expenses and liabilities.
• The ability to use net operating loss carryforwards to offset future taxable income may be subject to limitations due to ownership changes (e.g., Section 382 of the Code).

Future Outlook

The company expects to continue incurring operating losses and cash outflows in the near-term as it builds commercial and clinical infrastructure and pursues further regulatory clearances for the ALLY System. Annual revenue and selling, general and administrative expenses are expected to increase with ALLY System placements. Liquidity is believed to be sufficient for at least 12 months, but additional capital may be needed in the future through equity or debt financings. The merger with Alcon is expected to close in the second half of 2025, subject to regulatory approvals. The new U.S. tax legislation (OBBBA) is being evaluated for its impact on cash from operations.

Management Comments

• We expect to continue to incur losses and cash outflows from operating activities for the near-term future.
• Management believes the Company’s cash, cash equivalents, and investments on hand, together with cash generated from the future sale and lease of products, will provide sufficient funds for its operating, investing, and financing cash flows for a period of at least twelve months from the date of issuance of these financial statements.
• We expect annual revenue and selling, general and administrative expenses to increase from current levels associated with the increase in ALLY System placements.
• The Company continues to expect that the Merger will be completed in the second half of 2025, subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction or waiver of the other closing conditions specified in the Merger Agreement, including approval by our stockholders, which occurred on July 2, 2025.

Industry Context

LENSAR operates in a highly competitive global medical device market for cataract treatment, facing large multinational companies and smaller innovators. The industry is characterized by rapid technological changes. The company's ALLY System integrates AI and robotic technologies, aiming for operational efficiencies in premium cataract surgery. Reimbursement policies, particularly for advanced procedures not fully covered by Medicare or private insurance, significantly influence market adoption. Global macroeconomic conditions, supply chain disruptions, and tariffs are impacting costs and potentially demand across the industry. Evolving regulatory frameworks for medical devices (e.g., EU MDR, UK MDR) and AI technologies are creating new compliance challenges and costs.

Comparison to Industry Standards

• The company's ALLY System competes with offerings from major players like Alcon Inc., Bausch + Lomb Corporation, Johnson & Johnson, Carl Zeiss AG, Zeimer, and KERANOVA S.A.
• LENSAR's reliance on patient out-of-pocket payments for advanced cataract procedures contrasts with standard procedures covered by Medicare or private insurance, which is a common challenge for premium technologies in the ophthalmology sector.
• The company's lack of its own intraocular lens (IOLs) could be a competitive disadvantage compared to competitors who offer integrated solutions.
• The impact of South Korea's Supreme Court ruling on insurance benefits for cataract surgeries, leading to reduced revenue, highlights the sensitivity of the market to changes in reimbursement policies, a common industry-wide risk.
• The company's installed base of approximately 410 systems as of June 30, 2025, provides a benchmark for its market penetration relative to competitors' installed bases, though specific competitor numbers are not provided in the filing.

Corporate Governance

Legal Proceedings

• The company may become involved in various legal proceedings relating to matters incidental to the proposed Merger and in the ordinary course of business, including intellectual property, commercial, product liability, employment, class action, whistleblower, and other litigation and claims, and governmental and other regulatory investigations and proceedings.
• Demand letters have been received from purported stockholders alleging deficiencies/omissions in proxy statements related to the merger.
• A demand from a purported stockholder seeking to inspect corporate books and records to investigate alleged breaches of fiduciary duty by board members in connection with the merger has been received.

Related Party Transactions

• In May 2023, the company completed a Private Placement with NR-GRI Partners, LP (an affiliate of North Run Capital, LP), involving the sale of Series A Redeemable Convertible Preferred Stock and Warrants.
• Thomas B. Ellis and Todd B. Hammer, co-managing partners of North Run, joined the company's Board of Directors.
• In June 2023, the company entered into an international distribution agreement in India with a company owned by an employee at that time; this related party relationship ended on April 1, 2024.
• NR-GRI and its affiliates hold 45.6% of the voting power and have consent rights over certain corporate actions.

Stakeholder Impact

• Shareholders: Potential for significant cash consideration ($14.00 per share) plus a contingent value right ($2.75 per share) if the Alcon merger closes. However, merger delays and risks could impact stock price. Dilution risk from future capital raises. North Run Capital's significant ownership limits influence of other shareholders.
• Employees: Uncertainty regarding future employment and retention given the pending merger with Alcon. Executive officers have interests in the merger (equity awards vesting, prorated bonuses, severance benefits).
• Customers: Continued availability and innovation of ALLY System and LLS. Potential for increased costs due to tariffs not being passed on, or future price increases if costs are passed on. Impact of regulatory changes on procedure coverage (e.g., South Korea) affecting demand.
• Suppliers: Risks of supply chain disruptions, inflationary pressures, and tariffs impacting component availability and pricing.
• Regulatory Authorities: Ongoing engagement with FTC for merger review, and FDA/foreign bodies for product clearances and compliance.

Next Steps

• Respond promptly and cooperatively to the FTC's Second Request for the Alcon merger.
• Continue efforts to close the Alcon merger in the second half of 2025.
• Continue to build commercial and clinical infrastructure.
• Pursue further regulatory clearances and certifications for the ALLY System in additional jurisdictions, including China.
• Evaluate the impact of the new U.S. tax legislation (OBBBA) on cash from operations and adjust estimates.
• Monitor and manage supply chain disruptions, inflationary pressures, and tariffs impacting costs.
• Continue to grow the U.S. direct sales organization and international distributor network.
• Potentially raise additional capital through equity or debt financings if needed.
• Address ongoing legal proceedings and demand letters related to the merger.
• Adapt to evolving regulatory frameworks for medical devices and AI technologies.

Key Dates

Recommendation

The company shows positive revenue growth driven by its ALLY System and a significant reduction in Q2 net loss. However, the pending Alcon merger, while offering a premium, faces regulatory hurdles and associated costs. The substantial YTD net loss due to warrant revaluation, ongoing operational losses, and the need for future capital raises introduce considerable uncertainty. The stock's performance is heavily tied to the merger's completion and the successful commercialization of the ALLY System in a competitive and regulated market. Investors should hold, awaiting clarity on the merger and sustained operational profitability.

Keywords

LENSAR, ALLY System, Cataract Surgery, Robotic Laser, Medical Device, SEC Filing, 10-Q, Financial Results, Alcon Merger, Acquisition, Ophthalmology, Healthcare Technology, FDA Clearance, EU Certification, Risk Factors, Intellectual Property, Corporate Governance, Supply Chain, AI Technologies